ColubrisMX, Inc. Announces Corporate Rebranding to ENDOQUEST Robotics™

New brand identity highlights company leadership in advancing innovative “scar-free” technology for endoluminal robotic surgeries.

ColubrisMX, Inc., developer of the world’s first flexible endoluminal robotic system which enables scar-free and less invasive surgical procedures, today announced that the Company has rebranded to ENDOQUEST Robotics™ (“ENDOQUEST”).  The Company also announced the simultaneous launch of its new website, www.endoquestrobotics.com.

Since being founded, our company has made rapid progress in the development of technologies that represent historic advances in endoluminal surgery, with the potential to bring millions of patients access to procedures that are less invasive and scar-free,” said Kurt Azarbarzin, Chief Executive Officer of ENDOQUEST Robotics.  “This rebranding as ENDOQUEST Robotics reinforces our commitment to being the leader in innovation in flexible robotic technology for a wide range of needs in endoscopic surgeries in the years ahead.”

ENDOQUEST’s advanced robotic platform enables therapeutic endoscopists and surgeons to perform endoluminal surgeries through the body’s existing lumens, eliminating the need for incisions that lead to visible scarring.  ENDOQUEST’s Endoluminal Surgical (ELS) System combines the flexibility of conventional endoscopy with the advantages of traditional surgical techniques that can improve control and precision.  The Company’s proprietary endoscope is a flexible and steerable overtube that functions as a robotic delivery system able to deliver two surgical instruments and a flexible videoscope to a surgical target. With the enhanced capabilities of the ENDOQUEST ELS System, advanced endoscopists and surgeons can access locations in the digestive tract through a body’s natural orifice using traditional surgical techniques not previously possible.

“Following completion of our successful $76 million Series C financing, we remain very encouraged by the growing levels of investor, gastroenterologist and surgeon interest in our ELS System technology and are working aggressively to advance this development program to an Investigational Device Exemption (IDE) filing with the U.S. Food and Drug Administration,” Azarbarzin added.  “We look forward to providing an update on our progress on July 1, 2022 at the Society of Robotic and Digital Surgery’s Annual Meeting at the Disney World Yacht and Beach Club Resort in Lake Buena Vista, Florida.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version